智通财经APP获悉，中生制药(01177)再涨超6%，截至发稿，涨5.44%，报8.14港元，成交额10.77亿港元。
消息面上，中生制药认为，选择性HER2酪氨酸激酶抑制剂宗艾替尼再次获得中国国家药品监督管理局药品审评中心（CDE）突破性治疗资格认定，适用于治疗携带HER2酪氨酸激酶结构域（TKD）激活突变的不可切除或转移性非小细胞肺癌（NSCLC）成人患者的一线治疗。此次突破性治疗资格认定是基于其BeamionLUNG-1临床试验数据。
花旗发布研报称，中国生物制药上半年净利润34亿元人民币，同比增长140%；收入176亿元人民币，同比增长10.2%，利润及收入均超出市场共识及花旗预期。中生制药管理层对创新候选药物的授权许可潜力充满信心，包括TQC3721(PDE3/4)。中金预计，公司未来三年的创新产品获批进度有望加快，为公司带动更多收入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.